| Literature DB >> 25446019 |
Marie-Lucile Figueres1, Agnès Linglart2, Frank Bienaime3, Emma Allain-Launay4, Gwenaelle Roussey-Kessler5, Amélie Ryckewaert6, Marie-Laure Kottler7, Maryvonne Hourmant8.
Abstract
Loss-of-function mutations of CYP24A1, the enzyme that converts the major circulating and active forms of vitamin D to inactive metabolites, recently have been implicated in idiopathic infantile hypercalcemia. Patients with biallelic mutations in CYP24A1 present with severe hypercalcemia and nephrocalcinosis in infancy or hypercalciuria, kidney stones, and nephrocalcinosis in adulthood. We describe a cohort of 7 patients (2 adults, 5 children) presenting with severe hypercalcemia who had homozygous or compound heterozygous mutations in CYP24A1. Acute episodes of hypercalcemia in infancy were the first symptom in 6 of 7 patients; in all patients, symptoms included nephrocalcinosis, hypercalciuria, low parathyroid hormone (PTH) levels, and higher than expected 1,25-dihydroxyvitamin D levels. Longitudinal data suggested that in most patients, periods of increased sunlight exposure tended to correlate with decreases in PTH levels and increases in calcemia and calciuria. Follow-up of the 2 adult patients showed reduced glomerular filtration rate and extrarenal manifestations, including calcic corneal deposits and osteoporosis. Cases of severe PTH-independent hypercalcemia associated with hypercalciuria in infants should prompt genetic analysis of CYP24A1. These patients should be monitored carefully throughout life because they may be at increased risk for developing chronic kidney disease.Entities:
Keywords: 1,25-dihydroxyvitamin D (1,25[OH](2)D); 24α-hydroxylase; CYP24A1; chronic kidney disease (CKD); hypercalcemia; hypercalciuria; hypervitaminosis D; idiopathic infantile hypercalcemia (IIH); nephrocalcinosis; parathyroid hormone (PTH); vitamin D metabolism
Mesh:
Substances:
Year: 2014 PMID: 25446019 DOI: 10.1053/j.ajkd.2014.06.037
Source DB: PubMed Journal: Am J Kidney Dis ISSN: 0272-6386 Impact factor: 8.860